G protein-coupled receptor antagonists

Details G protein-coupled receptor antagonists G protein-coupled receptor antagonists

2006-09-12

2006-09-12

Andres, Janet L. (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S017400, C514S018700, C514S019300, C530S328000, C530S333000, C530S333000, C536S023500, C435S007210, C436S501000

Reexamination Certificate

active

07105488

ABSTRACT:
G-protein coupled receptors (GPCR) generally contain seven transmembrane helices. The present invention provides synthetic peptides derived from these transmembrane helices. The peptides inhibit GPCR function by disrupting GPCR structure. In certain embodiments, charged residues are added at one terminus to promote correct orientation of the peptide in the membrane.

REFERENCES:
patent: 5508384 (1996-04-01), Murphy et al.
patent: WO 94/05695 (1994-03-01), None
patent: WO 97/28258 (1997-08-01), None
patent: WO 97/35881 (1997-10-01), None
patent: WO 98/00538 (1998-01-01), None
Ulrich et al., Biochem. Biophys. Res. Comm. 193(1)204-211, 1993.
Bowie et al., 1990, Science 247:1306-1310.
Guo-HH et al. PNAS 101(25)9205-9210, 2004.
Anand-Srivastava et al. (1996) “Cytoplasmic Domain of Natiuretic Peptide Receptor-C Inhibits Adenylyl Cyclase”, J. Biol.Chem. 271:19324-19329.
Gudermann et al. (1997) “Functional and structural complexity of signal transduction via G-protein-coupled receptors”, Annu. Rev. Neurosci. 20:399-427.
Hebert et al. (1996) “A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation”, J. Biol. Chem. 71(27):16384-92.
Merkouris et al. (1996) “Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides”, Mol. Pharmacol. 50(4):985-93.
Monnot et al. (1996) “Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants”, J. Biol. Chem. 271(3):1507-13.
Moro et al. (1993) “Hydrophobic amino acid in the i2 loop plays a key role in receptor -G protein coupling”, J. Biol. Chem. 268:22273-6.
Osuga et al. (1997) “Co-expression of defective luteinizing hormone receptor fragments partially reconstitutes ligand-induced signal generation”, J. Biol. Chem. 272:25006-12.
Raport et al. (1996) “Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha”, J. Biol. Chem. 271:17171-17166.
Schoneberg et al. (1996) “Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide”, EMBO J. 15:1283-91.
Wong et al. (1990) “Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists”, J. Biol. Chem. 265:6219-6324.

Affiliated with

Also associated with

Rating

G protein-coupled receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with G protein-coupled receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and G protein-coupled receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3599124